SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results topped expectations and marked its first profit since its IPO, with rapid growth in its AI-compute business and plans for heavy infrastructure spending driving attention. Many traders welcomed the growth and outlook, while others questioned the valuation, spending and share-unlock risk; discussion of a possible Tesla merger added speculation, but no deal is assured.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary first-quarter update sharply raised its revenue and gross-margin outlook, citing stronger AI-platform demand, sparking a surge in shares. Traders largely welcomed the update as evidence of robust AI-server demand and anticipated short covering, while some questioned whether the gains would hold given the companys execution and credibility concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer fourth-quarter guidance, slowing revenue growth and a reduced advertising outlook, prompting a sharp selloff. Traders are debating whether the drop reflects worsening growth prospects or an overreaction to the outlook, with some pointing to continued profitability as a reason to buy the dip.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas rebound is drawing attention amid confirmed formation of special committees to explore a potential SpaceX merger, though Musk said a deal is uncertain and would require shareholder support. Traders are split between enthusiasm over possible synergies and skepticism about the terms and timing, while positioning around Teslas Q3 earnings adds volatility.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is being swept up in a sharp memory-chip and Korean-market selloff, with traders citing KOSPI weakness, foreign selling, and fears about Chinese competition and the durability of the AI-driven memory cycle. Bulls argue the decline is excessive given strong memory demand and low valuations, while bears see further downside risk from cyclical and oversupply concerns.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Q3 earnings expectations dominate, with traders debating whether results and guidance can support Bloom Energys premium valuation after a sharp pullback. Bulls point to fuel-cell demand from AI data centers, while skeptics cite valuation risk and broader weakness in AI-related stocks.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads sharp rally is driven mainly by its agreement to sell its prenatal testing business to Labcorp for $210 million in cash plus inventory value, which traders view as a major cash infusion and a shift toward oncology. Bulls see the deal as a balance-sheet and strategic positive, while skeptics argue that selling a revenue-generating unit leaves a smaller business with ongoing debt and execution concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDAs acceptance of REZZAYOs supplemental application for Priority Review is drawing attention, with traders focused on a possible expansion into invasive-fungal-disease prevention and the pending FDA decision. Optimism about that opportunity is tempered by concerns over DefenCath reimbursement and adoption, management execution, and the stocks muted response to positive developments.

Braze, Inc. operates a customer relationship management platform for mobile applications. Its application combines messaging, audience segmentation, analytics and user support in a single integrated solution. The firm offers push notifications, email, in-app messages, and news feed services. The company was founded by Mark Ghermezian, William Magnuson, and Jonathan Hyman on March 28, 2011 and is headquartered in New York, NY.

Braze Inc - Ordinary Shares - Class A

Braze Inc

Salesforces agreed cash acquisition of Braze at a substantial premium is driving the sharp share-price surge, with traders celebrating the buyout while weighing the remaining merger-arbitrage spread and the long wait for the deal to close. Analysts post-deal downgrades have also prompted discussion, though some view the transaction as a win for shareholders and a potential boost to software-sector deal activity.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in acute bipolar mania met its primary and secondary endpoints, prompting a burst of bullish interest. Traders are divided over whether the efficacy is strong enough to outweigh concerns about agitation and higher treatment discontinuations, with the initial rally fading amid profit-taking and short-selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcare ETFs to Buy as UnitedHealth Beats on Q3 Earnings

UnitedHealth's Q3 earnings beat estimates, lifting shares 6.3%. Explore three healthcare ETFs offering UNH exposure while diversifying Medicaid risks. 

Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs

Trump's latest MFN drug-pricing deals create a mixed outlook for the broader healthcare sector ETFs. 

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets 

Equity

CEO Jeff Tangney said Doximity's AI recorded a 4.8% error rate versus 13.6% for Anthropic's Fable 5.


UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch

 UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.

Goldman Sachs Lifts UnitedHealth Target Price: Healthcare ETFs to Watch

Goldman lifts UnitedHealth's target price, spotlighting ETFs like IHF as diversified ways to tap its growth while cushioning Medicaid-driven risks.

The Zacks Analyst Blog Highlights SPY, DIA, QQQ, WCLD, XTL, RSPC, IHF and XOP

Several sector ETFs, including WCLD, XTL and XOP, are holding steady and even gaining despite market volatility tied to Middle East tensions.

5 Sector ETFs Held Steady Amid Iran Conflicts 

Iran tensions rattle markets, but select sector ETFs stay resilient. Here are 5 funds gaining momentum amid volatility.

iShares Trust - iShares U.S. Healthcare Providers ETF

Neutral Sentiment

<ul class="summary-bullets"><li>CEO Jeff Tangney attributed Doximity’s performance over Anthropic to proprietary medical data and physician oversight.</li><li>Canaccord and BMO Capital raised their price targets on Doximity, citing growing demand for the company's AI products.</li><li>Canaccord forecast that AI revenue would become a meaningful growth driver in the third quarter.</li></ul>Shares of Doximity (DOCS) surged as much as over 200% in pre-market trade on Friday before paring most of the gains despite an earnings miss after CEO Jeff Tangney touted the company’s growing artificial intelligence capabilities and said that its clinical AI outperformed Anthropic's latest model in physician-focused testing.&nbsp;During the earnings call, Chief Executive Jeff Tangney said Doximity's clinical AI recorded a 4.8% error rate, compared with 13.6% for what he called Anthropic's “best model”, Fable 5.Canaccord also raised its price target on DOCS stock to $36 from $30 and kept a ‘Buy’ rating on the shares, citing growing demand for Doximity's AI products, especially from pharmaceutical companies. Meanwhile, BMO Capital raised its price target to $30 from $20 and kept a ‘Market Perform’ rating on the shares.&nbsp;DOCS stock more than tripled at one point in pre-market trading before the rally cooled to about 100%, putting the shares on track to hit a six-month high. The stock was among the top trending tickers on Stocktwits, and on track to hit highs not seen since January.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/DOCS_2026_08_07_07_30_17_c573acda34.png" alt="DOCS_2026-08-07_07-30-17.png" width="2643" height="1588"><figcaption>DOCS stock’s performance year-to-date. | Source: TradingView</figcaption></figure>If the gains hold above 40%, the rally would mark the biggest single-day gain in the stock's history, surpassing the previous record of 38.74% set in August 2024.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260807_072949232_ff7ee6d5f9.png" alt="koyfin_20260807_072949232.png" width="2400" height="1240"><figcaption>DOCS stock’s historical single-day gains. | Source: Koyfin</figcaption></figure><h2 class="st-heading-2">Doximity Says Its AI Outperformed Anthropic</h2>Tangney said Doximity’s performance advantage over Anthropic stemmed from two key differentiators. The first is a built-in, expert-verified drug reference system designed to improve dosing accuracy and drug interaction checks. The other is a network of more than 12,000 physician "PeerCheck" editors who continuously review and refine the platform's AI-generated responses."We're proving you can still post best-in-class software margins while investing heavily in clinical AI," Tangney said. "We're leaning in because we see a once-in-a-generation opportunity to build the new AI age of medicine."He added that AI represents "the next chapter" in Doximity's growth strategy, building on its position as a digital platform for physicians.<h2 class="st-heading-2">Canaccord Sees AI Becoming A Major Growth Driver</h2>The brokerage said AI revenue has yet to materially contribute to Doximity's financial results but is already generating meaningful customer interest.&nbsp;Analysts pointed to growing demand from pharmaceutical companies for Doximity's AI tools, particularly search marketing capabilities within its "Ask" platform, which they said is driving engagement with clients.Canaccord expects meaningful AI monetization to begin in the third quarter, with the segment becoming an increasingly important contributor to the company's long-term growth.BMO Capital echoed the view, stating AI Search traction and increased AI utilization support long-term monetization. However, the firm added that near-term margin pressure from higher compute costs may weigh on the balance sheet.<h2 class="st-heading-2">How Is Retail Feeling About DOCS Stock?</h2>On Stocktwits, retail sentiment around DOCS stock improved to ‘extremely bullish’ from ‘bullish’ over the past day, while chatter rose to ‘extremely high’ from ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_08_07_070424_1_03bfe0a28d.png" alt="Screenshot 2026-08-07 070424 (1).png" width="1274" height="684"><figcaption>DOCS stock retail sentiment on August 7 as of 7:45 a.m. ET | Source: Stocktwits</figcaption></figure>Many retail traders on the platform warned that the rally in DOCS might be a short squeeze in the making.<stembedurl>https://www.stocktwits.com/Iorgi/message/661226224</stembedurl><stembedurl>https://www.stocktwits.com/AsymmetricUpsideEnjoyer/message/661231790</stembedurl>Not accounting for the pre-market rally, DOCS stock has dropped more than 50% this year and nearly 65% in the last 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soun-stock-hits-2-month-high-biggest-single-day-gain-price-target-cuts/cZoBcXZRJJE">SOUN Stock Hits 2-Month High, Rallying Toward Biggest Gain in 3 Months Despite Analyst Target Cuts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Doximity, Inc. logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

CEO Jeff Tangney said Doximity's AI recorded a 4.8% error rate versus 13.6% for Anthropic's Fable 5.

DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets

Doximity Inc

iShares U.S. Healthcare Providers ETF

iShares Core S&P Mid-Cap ETF

Vanguard Health Care ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

IHF iShares U.S. Healthcare Providers ETF

Fundamentals

Latest IHF News